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Diagnosing an Infection Control Risk
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If there wasn’t cause enough in the alarming increase and plateau at historic highs of C. 
difficile infections (CDI) and associated deaths [1], the recent addition of hospital-onset CDI 
to the ‘pay for performance’ program administered by the Center for Medicare & Medicaid 
Services [2] has further increased the ante on prevention. Yet there is controversy and 
potential change in two key areas pertaining to the treatment and prevention of CDI that the 
article by Mawer et al. in this issue of Clinical Infectious Disease traverses [3]. One is the 
uncertainty surrounding the best method to diagnose CDI; the other is the relative 
importance of different sources of C. difficile transmission in the hospital.
Following the approval of the first nucleic acid amplification tests (NAATs) approximately 
eight years ago, there has been increasing adoption so that recent data from the National 
Healthcare Safety Network laboratory survey indicates 65% of hospital laboratories were 
using a NAAT in the last quarter of 2015 while additional laboratories used an algorithm that 
incorporated a NAAT (unpublished data). Recent observational studies have called into 
question whether symptomatic, NAAT+ patients who are toxin enzyme immunoassay (EIA) 
negative may be only colonized with C. difficile, with diarrhea resulting from other causes, 
suggesting these patients should not be treated [4, 5]. Current recommendations in the 
United Kingdom are to not treat NAAT+/toxin EIA- patients but consider them colonized 
and a potential, but heretofore unquantified, infection control risk [3]. Meanwhile in the 
United States it remains standard practice to both treat and isolate all NAAT+ patients. 
Multistep algorithms that could potentially provide clinicians with an assessment of both the 
presence or absence of a toxigenic organism, as well as some sense of the presence or 
absence of toxin in stool, are used in a minority of U.S. hospitals; even for those settings 
with such results available, it has not been demonstrated how clinicians should combine 
results with the clinical context of specific patients to alter management.
Regarding the relative importance of different sources of transmission in the hospital 
environment, acquisition of C. difficile from another (symptomatic) patient with CDI has 
been long-thought the principal source; current infection control recommendations focus on 
the containment of transmission from these patients. This paradigm appears now in a state of 
flux as, at least in hospitals with modern infection control programs, patients commonly 
isolated and treated for CDI serve as the source for only approximately one third of new 
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healthcare-associated cases [6, 7]. Of note, Mawer et al. found as few as 19% of new CDI 
cases resulted from transmission from another symptomatic patient--they attribute this 
decline from their previous study [6] to the decline in the hypervirulent ribotype 027 strain 
[3].
It is in this context of controversy over the best methods for clinical diagnosis and changing 
importance of different sources of transmission, that the study by Mawer et al. addresses an 
important question: “To what extent do symptomatic patients with toxigenic C. difficile in 
their stool but no readily detected toxin pose an infection control risk?” The methods 
employed at two hospitals in England involved screening with an EIA for glutamate 
dehydrogenase (GDH) followed by toxigenic culture and, depending upon the facility, toxin 
A/B EIA and/or cell culture cytotoxin neutralization assay (CCNA). The results generated 
should be roughly generalizable to settings that employ either a GDH/toxin EIA/NAAT or 
NAAT/toxin EIA algorithm, despite GDH tests being somewhat less sensitive than NAAT 
for the detection of toxigenic organism and the better performing toxin EIAs being similarly 
less sensitive than CCNA for detection of toxin. Mawer et al. sort out likely transmission 
events using whole genome sequencing and single polynucleotide polymorphism (SNP) 
methods similar to their previous studies [6].
Using abbreviations for toxigenic strain (TS) based upon GDH/toxigenic culture results, and 
fecal toxin (FT), based upon a mix of CCNA and toxin EIA, patients who were TS+/FT+ 
were the source of transmission for 10% of subsequent TS+/FT+ cases while those who 
were TS+/FT− were the source for 3%, and both TS+/FT+ and TS+/FT− patients were 
implicated as potential sources for 6% of TS+/FT+ cases. Results were similar in 
considering sources for subsequent TS+/FT+ and TS+/FT− cases combined.
While these results were presented as the contribution of various transmission sources to the 
total of all healthcare-associated cases, as Mawer et al. point out in their discussion, this 
does not account for the greater number of TS+/FT+ compared to TS+/FT− potential source 
patients. Although a more accurate risk calculation may be achieved using a 3-month ‘lead 
out’ period at the end of the study (similar to the 3 month ‘lead-in’ period used during which 
no sources were sought for new cases) or possible use of survival analysis (i.e., determining 
time dependent risk and censoring potential sources at the end of the study period), if one 
divides the number of cases attributed to both FT+ and FT− sources equally to each source 
group, one can produce a crude estimate from the available data of the risk that a FT+ or FT
− potential source would transmit. Thus the risk that a TS+/FT+ potential source would 
transmit resulting in a subsequent TS+/FT+ case was 6.8% (34.5/507) or, resulting in either 
a TS+/FT+ or TS+/FT− case, 9.4% (47.5/507). Similarly, the risk that a TS+/FT− potential 
source would transmit resulting in a subsequent TS+/FT+ case was 4.7% (16.5/353) or, 
resulting in either a TS+/FT+ or TS+/FT− case, 7.8% (27.5/353).
What emerges from these calculations, and is also touched on in the discussion by Mawer et 
al., is that while TS+/FT+ cases are most contagious, TS+/FT− cases are a close second and 
both groups are much more contagious than asymptomatic carriers. Data on both organism 
load and skin and environmental contamination appear to support this ordering in the 
magnitude of contagiousness [8, 9]. However, while asymptomatic carriers (who are much 
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more numerous) are overall less contagious, there may be some who, either because of 
ongoing antibiotic exposure or other factors, are similarly contagious as these symptomatic 
groups. For example, Curry et al. found in asymptomatic C. difficile carriers detected among 
patients at high risk for colonization with vancomycin resistant enterococci that the risk for 
onward transmission resulting in a TS+/FT+ (detected via CCNA) case was 7% (16/226)[7]. 
In the recent study by Longtin et al. that demonstrated a 62% reduction in healthcare-
associated CDI through the detection and isolation of asymptomatic carriers, reduced 
antibiotic prescribing in carriers was hypothesized as a potential means through which some 
of the reduction was effected [10]. While such a reduction in prescribing may be conjectured 
to decrease progression from carrier status to active CDI, it may also simply maintain 
carriers at a less contagious state.
Because any estimate of the contagiousness or reproductive potential of different case types 
or carriers is highly dependent upon the timing and nature of infection control precautions as 
well as clinical treatments that impact organism load, the heterogeneity of these practices 
between and across the two study sites is a potential limitation of this study [3]. There was a 
lower threshold for isolation and clinical testing (i.e. ≥ 1 episode of unexplained diarrhea), as 
well as use of a potentially more sensitive toxin assay (CCNA) at Leeds. However, at Oxford 
all patients with > 3 episodes of unexplained diarrhea in 24 hours were immediately begun 
on empiric oral vancomycin that was discontinued in FT− patients. Given that transmission 
risk as calculated above (especially from TS+/FT+ patients) was somewhat lower at Oxford 
(data not shown), this practice may have favorably impacted transmission through an early 
and more immediate reduction in organism load. Meanwhile, it is not known how often 
patients at Leeds were treated with vancomycin and how often TS+/FT− patients at either 
study site remained in (or were placed back into) isolation.
Regardless of these limitations, this study further highlights how properly designed 
epidemiologic transmission studies that employ whole genome sequencing and SNP analysis 
can be applied to answer important questions critical to clinical medicine and public health. 
For now it appears that before instituting broad strategies of active surveillance and isolation 
of all asymptomatic carriers, hospitals should first work to detect and isolate all or most 
symptomatic patients who are TS+. Future studies should be designed to determine which 
asymptomatic patients should be subsequently prioritized for screening and isolation to 
further reduce in-hospital transmission.
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